Church & Dwight
CHD
$95.09
+1.69%
Church & Dwight Co., Inc. is a leading consumer packaged goods company operating in the Household & Personal Products industry, best known as the global leader in baking soda production and for its powerhouse Arm & Hammer brand. The company has successfully expanded its portfolio beyond its legacy product into a diversified suite of essential categories including laundry care, cat litter, oral care, deodorant, and vitamins through brands like OxiClean, Vitafusion, and TheraBreath. As a stable, defensive player with approximately 80% of sales derived from the US market, the current investor narrative centers on its ability to navigate a competitive landscape through brand investment and strategic acquisitions, such as the recent addition of Touchland's hand sanitizer business, while demonstrating resilient growth and margin performance in a challenging cost environment.…
CHD
Church & Dwight
$95.09
Investment Opinion: Should I buy CHD Today?
Rating & Thesis: Hold. CHD is a high-quality, defensive business trading at a full valuation that leaves little margin for error, warranting a neutral stance until growth re-accelerates or the multiple contracts to a more attractive level. The limited analyst coverage provides no strong consensus push, but the company's underlying fundamentals remain solid.
Supporting Evidence: The stock's forward PE of 24.02x is a premium to typical consumer staples. Revenue growth of 3.93% YoY in Q4 is positive but slowing. Profitability is strong with a net margin of 11.88% and robust free cash flow generation of $1.093 billion TTM. The technical picture shows the stock consolidating in the lower half of its 52-week range ($81.33-$106.04), suggesting it is not overextended but lacks near-term momentum.
Risks & Conditions: The two biggest risks are multiple compression and prolonged growth deceleration. This Hold rating would upgrade to a Buy if the forward PE compresses below 20x (offering a better margin of safety) or if quarterly revenue growth re-accelerates sustainably above 6% YoY. It would downgrade to Sell if revenue growth turns negative or if operating margins show sustained contraction. Relative to its history and sector, the stock is fairly valued to slightly overvalued, pricing in its quality but offering limited near-term upside.
Sign up to view all
CHD 12-Month Price Forecast
The outlook for CHD is one of stable, low-growth consolidation. The company's excellent fundamentals are offset by a rich valuation that leaves little room for multiple expansion, the likely path for the stock is sideways to slightly upward movement driven by earnings growth and dividends. The stance is neutral with medium confidence, as the downside appears limited by the strong balance sheet and cash flow, but the upside is capped without a growth re-acceleration. We would upgrade to bullish if the stock trades below a 20x forward PE or if organic growth sustainably exceeds 5%. A downgrade to bearish would be triggered by a breakdown below the $81 support level on deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Church & Dwight's 12-month outlook, with a consensus price target around $123.62 and implied upside of +30.0% versus the current price.
Average Target
$123.62
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$76 - $124
Analyst target range
Analyst coverage for CHD is limited, with only 4 analysts providing estimates, which is low for a company of its market cap and suggests it may be under-followed by the broader institutional research community. The available analyst data points to estimated EPS averaging $4.71 for the period, with a narrow range from $4.67 to $4.80, indicating strong consensus on near-term earnings potential despite the low coverage count. The implications of limited coverage are meaningful; it can lead to higher volatility and less efficient price discovery, as the stock's narrative is shaped by fewer voices, though its status as a established, dividend-paying company in a defensive sector may attract steady investor interest regardless.
Bulls vs Bears: CHD Investment Factors
The evidence presents a balanced but cautious picture, with the bear side holding a slight edge due to the critical tension between CHD's premium valuation and its decelerating growth trajectory. The bull case is anchored in the company's defensive qualities, strong cash generation, and improving margins. However, the bear case is compelling because a forward PE of 24x demands a growth rate that the recent 3.93% YoY revenue increase does not support. The single most important factor in the investment debate is whether CHD can re-accelerate organic growth to justify its valuation premium, or if multiple compression is inevitable as the market reprices it as a slower-growth staple. The stock's current technical consolidation reflects this uncertainty.
Bullish
- Strong Profitability & Cash Flow: The company generates robust net margins of 11.88% and a trailing twelve-month free cash flow of $1.093 billion. This provides ample internal funding for dividends, buybacks, and strategic acquisitions without straining its conservative balance sheet, which has a low debt-to-equity ratio of 0.55.
- Defensive, Low-Volatility Profile: With a beta of 0.473, CHD is less than half as volatile as the broader market, offering a defensive haven. This characteristic is attractive in uncertain economic environments, as evidenced by its positive 1-year return of 3.94% even while underperforming the S&P 500's 29.04% surge.
- Resilient Margins and Diversified Portfolio: Gross margins improved to 45.85% in Q4 2025 from a TTM figure of 44.73%, demonstrating pricing power and cost management. The portfolio, with 70% of sales from powerhouse brands like Arm & Hammer and OxiClean, provides stability against category-specific downturns.
- Technical Consolidation Near Support: The stock is trading at approximately 60% of its 52-week range, closer to its 52-week low of $81.33 than its high of $106.04. This positioning after a pullback from February highs suggests a potential value entry point, with the low beta indicating a likely muted downside from current levels.
Bearish
- Premium Valuation vs. Slowing Growth: CHD trades at a premium trailing PE of 27.62x and forward PE of 24.02x, which is elevated for a consumer defensive stock. This valuation is difficult to justify given decelerating revenue growth, with Q4 2025 YoY growth of 3.93% and a sequential decline from Q3.
- Significant Underperformance vs. Market: The stock's 1-year return of +3.94% lags the S&P 500 by over 25 percentage points, indicating a lack of momentum and weak relative strength. This underperformance, coupled with a negative 3-month relative strength of -4.38%, suggests waning investor interest in the near term.
- Limited Analyst Coverage & Visibility: Only 4 analysts cover the stock, which can lead to less efficient price discovery and higher volatility. While EPS estimates are tightly clustered, the low coverage count reflects a potential lack of institutional research interest, which may limit positive catalyst-driven rallies.
- High Geographic Concentration Risk: Approximately 80% of sales are derived from the US market, exposing the company to domestic economic cycles and competitive pressures. This concentration limits growth optionality from faster-growing international markets and increases vulnerability to a US consumer slowdown.
CHD Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +3.94%, though it has significantly underperformed the broader market's 29.04% gain. As of the latest close at $96.02, the price is trading at approximately 60% of its 52-week range, positioned closer to the 52-week low of $81.33 than the high of $106.04, suggesting the stock is in a consolidation phase after a prior rally and may represent a relative value opportunity rather than being overextended. Recent momentum shows a short-term recovery, with a 1-month price increase of 3.41%, which contrasts with a slight 3-month decline of -0.24%, indicating a potential reversal from the recent pullback that began in late February. This divergence, where short-term momentum is positive against a flat medium-term trend, could signal the early stages of a mean reversion rally, supported by a low beta of 0.473 which implies the stock is less than half as volatile as the market. Key technical levels are clearly defined by the 52-week high of $106.04 as major resistance and the 52-week low of $81.33 as critical support; a breakout above resistance would confirm a resumption of the primary uptrend, while a breakdown below support could trigger a deeper correction, though the stock's low beta suggests such moves may be more muted compared to the overall market.
Beta
0.48
0.48x market volatility
Max Drawdown
-22.7%
Largest decline past year
52-Week Range
$81-$106
Price range past year
Annual Return
+1.1%
Cumulative gain past year
| Period | CHD Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +8.2% |
| 3m | -4.9% | +9.0% |
| 6m | +13.1% | +10.5% |
| 1y | +1.1% | +26.5% |
| ytd | +15.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHD Fundamental Analysis
Revenue growth remains positive but has shown signs of deceleration, with Q4 2025 revenue of $1.644 billion representing a year-over-year increase of 3.93%, a slowdown from the stronger growth rates seen in prior quarters of 2025. The quarterly trend reveals revenue sequentially declined from $1.587 billion in Q3, indicating potential near-term pressure, though the full-year trajectory is supported by the company's diversified brand portfolio. Profitability is robust, with the company generating a net income of $143.5 million in Q4 and a trailing twelve-month net margin of 11.88%, supported by a solid gross margin of 44.73% as per valuation data. Margins have demonstrated stability, with the Q4 gross margin of 45.85% showing improvement from the 44.73% trailing figure, and operating income of $266 million yielding a healthy operating margin of 16.18% for the quarter. The balance sheet is conservatively managed, evidenced by a debt-to-equity ratio of 0.55 and a strong current ratio of 1.07, indicating sufficient liquidity. The company generates substantial cash, with free cash flow over the trailing twelve months at $1.093 billion, providing ample internal funding for dividends, share buybacks, and strategic acquisitions without over-reliance on debt.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.03%
YoY Comparison
Gross Margin
+0.45%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHD Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 27.62x and a forward PE of 24.02x, with the forward multiple's discount to the trailing figure reflecting market expectations for modest earnings growth in the coming year. Compared to sector peers, Church & Dwight's valuation commands a significant premium; its trailing PE of 27.62x and Price-to-Sales (PS) ratio of 3.28x are elevated relative to typical consumer defensive staples, which often trade at lower multiples due to their slower growth profiles, suggesting the market is pricing in superior brand strength and execution. Historically, the current trailing PE of 27.62x sits above the stock's own multi-year range evident in the historical ratios data, where PE has fluctuated, including periods above 30x and below 25x; positioning near the higher end of its historical band indicates the market has largely priced in its quality and defensive characteristics, leaving limited room for multiple expansion.
PE
27.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -85x~40x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation compression, not operational weakness. The company's fundamentals are sound with a net margin of 11.88%, a strong current ratio of 1.07, and minimal debt burden (D/E of 0.55). However, the risk lies in its premium multiples (PE 27.62x, PS 3.28x) contracting if revenue growth, which decelerated to 3.93% YoY in Q4, fails to re-accelerate. Earnings could also face pressure if the recent gross margin improvement to 45.85% proves unsustainable amid input cost inflation.
Market & Competitive Risks: CHD faces significant market risk from its high valuation relative to the defensive staples sector. Trading at a forward PE of 24x, it is vulnerable to sector rotation out of expensive defensive names if economic optimism returns. Its low beta of 0.473, while defensive, also means it may not participate fully in market rallies, as seen in its 25-percentage-point underperformance versus the S&P 500 over the past year. Competitively, the company must continually invest in its core brands (70% of profits) to maintain shelf space against larger CPG rivals and private label incursion.
Worst-Case Scenario: The worst-case scenario involves a combination of an earnings miss, a guidance cut due to sustained consumer weakness, and a sector-wide de-rating of premium-valued staples. This could trigger a swift re-rating towards its historical valuation floor. The stock could realistically fall to retest its 52-week low of $81.33, representing a downside of approximately -15% from the current price of $96.02. A breach of that level could see a move towards the mid-$70s, aligning with a max drawdown historically around -26%, implying a potential total loss in the -20% to -25% range in a severe adverse scenario.
FAQ
The key risks are, in order of severity: 1) Valuation Compression: The premium forward PE of 24x could contract if growth slows further, posing a ~15-20% downside risk. 2) Growth Deceleration: Q4 revenue grew only 3.93% YoY; sustained low growth would challenge the investment thesis. 3) Market Underperformance: With a beta of 0.47, CHD may lag in strong bull markets, as seen in its 25% underperformance vs. the S&P 500 over the past year. 4) Geographic Concentration: 80% US sales exposure increases vulnerability to a domestic consumer downturn.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $95 and $105, driven by stable execution and its current valuation. The Bull Case (25% probability) targets $106 to $112 on re-accelerated growth and sustained premium multiples. The Bear Case (15% probability) envisions a drop to $81-$90 on growth disappointments and multiple compression. The Base Case is most likely, assuming the company maintains its current trajectory of low-single-digit growth and stable margins without major surprises.
CHD is fairly valued to slightly overvalued relative to its growth profile. Its trailing PE of 27.62x and forward PE of 24.02x command a significant premium to many consumer defensive peers, which typically trade at lower multiples due to slower growth. The market is pricing in CHD's superior brand strength, margin profile, and defensive characteristics. However, with revenue growth decelerating to 3.93% YoY, the current multiple implies expectations for stable execution but leaves little room for error. A more compelling valuation would be a forward PE closer to 20x.
CHD is a good stock for a specific type of investor: one seeking a defensive, low-volatility holding with reliable cash flow and a modest dividend. For investors prioritizing capital appreciation, it is less compelling at its current forward PE of 24x, given its low-single-digit revenue growth. The stock offers a potential 15% downside to its 52-week low but limited near-term upside beyond its recent high of $106. It is a good buy for conservative portfolios at a lower entry point, ideally below a 22x forward PE, but is fairly valued to slightly rich at present levels.
CHD is primarily suitable for long-term investment. Its low beta (0.473) and defensive characteristics make it a poor candidate for short-term trading, as it lacks the volatility for significant momentum plays. As a long-term holding, it offers stability, reliable dividend income (1.4% yield), and exposure to essential consumer brands. The company's strong free cash flow supports continued shareholder returns. A minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from the compounding effect of reinvested dividends and steady, if slow, earnings growth.